CERo Therapeutics Warrants
CEROW
CEROW was delisted on the 30th of October, 2025.
37 hedge funds and large institutions have $425K invested in CERo Therapeutics Warrants in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 8 closing their positions.
124% more capital invested
Capital invested by funds: $190K → $425K (+$235K)
8% less funds holding
Funds holding: 40 → 37 (-3)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$26.7K |
| 2 |
ACM
Atalaya Capital Management
New York
|
+$12.2K |
| 3 |
ICM
Ionic Capital Management
New York
|
+$4.88K |
| 4 |
CF
Cantor Fitzgerald
New York
|
+$4.71K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$848 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Segantii Capital Management
Hong Kong
|
-$55K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$22.2K |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$8.25K |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$5.8K |
| 5 |
CCM
Context Capital Management
Lajolla,
California
|
-$4.74K |
CEROW Hedge Fund Activity: Q1 2024 in Review
37 of the 6,960 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics Warrants (CEROW) for Q1 2024, worth a combined $425K — up 124% from $190K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CEROW and 6 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 4 added.
The largest buyer was Cowen and Company, adding an estimated $26.7K. The largest seller was Segantii Capital Management, exiting entirely with an estimated $55K sold.
- 37 institutional investors held CERo Therapeutics Warrants (CEROW) as of Q1 2024, down from 40 in Q4 2023.
- Funds reported $425K of CERo Therapeutics Warrants stock for Q1 2024, up 124% quarter-over-quarter.
- 6 funds opened new CERo Therapeutics Warrants positions in Q1 2024 and 8 closed out, a net change of -2 holders.
- The largest CERo Therapeutics Warrants buyer in Q1 2024 was Cowen and Company, an estimated $26.7K added.
- The largest CERo Therapeutics Warrants seller in Q1 2024 was Segantii Capital Management, an estimated $55K sold.
Based on aggregated 13F filings for Q1 2024.